Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Sodium lactate + calcium chloride + sodium chloride + magnesium chloride + dextrose monohydrate** is a multi-electrolyte **peritoneal dialysis solution** marketed as **DELFLEX** and developed/manufactured by Fresenius Medical Care for intraperitoneal administration in patients with chronic kidney failure maintained on peritoneal dialysis. The solution contains dextrose monohydrate as the principal osmotic agent plus sodium chloride, sodium lactate, calcium chloride, and magnesium chloride in water for injection; it is supplied in multiple formulations with differing dextrose strengths and electrolyte compositions, including standard and low magnesium/low calcium variants. Its therapeutic effect is not receptor-mediated; rather, it works by creating an osmotic gradient across the peritoneal membrane to promote ultrafiltration, while diffusion between blood and dialysate facilitates removal of uremic solutes and helps correct fluid and electrolyte abnormalities. Public labeling identifies initial U.S. approval for DELFLEX in 1984, with later approved configurations including attached exchange-set presentations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium lactate + calcium chloride + sodium chloride + magnesium chloride + dextrose monohydrate.